Thalidomide therapy induces response in relapsed mantle cell lymphoma
Open Access
- 1 September 2003
- journal article
- other
- Published by Springer Nature in Leukemia
- Vol. 17 (9) , 1914-1915
- https://doi.org/10.1038/sj.leu.2403058
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Differential regulation of dendritic cell function by the immunomodulatory drug thalidomideJournal of Leukocyte Biology, 2002
- Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective studyLeukemia, 2002
- Thalidomide for previously untreated indolent or smoldering multiple myelomaLeukemia, 2001
- Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaBlood, 2001
- Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase ActivityJournal of Biological Chemistry, 2001
- Thalidomide — A Revival StoryNew England Journal of Medicine, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-αThe Journal of Immunology, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994